PRESS RELEASE October 3, 2013

IMMUNE Pharmaceuticals Inc. to Present at 12th Annual BIO Investor Forum

TARRYTOWN, N.Y., Oct. 3, 2013 /PRNewswire/ — Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that Dr. Daniel G. Teper, Company Chairman and CEO, will be presenting at the 12th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum features leading private and emerging […]

Keep Reading

PRESS RELEASE September 30, 2013

Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States

TARRYTOWN, N.Y., Sept. 30, 2013 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange and OTCQX: IMNP) (“IMMUNE” or the “Company”) announced today that following the recent merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation, the Company will focus its capital raising efforts in the United States to support its objective to up-list to a U.S. […]

Keep Reading

PRESS RELEASE September 23, 2013

Immune Pharmaceuticals Inc. Trading Symbol is Now IMNP on Both NASDAQ OMX Stockholm Exchange and OTCQX Trading Platform

TARRYTOWN, N.Y., Sept. 23, 2013 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: IMNP, formerly EPCTD) announced today that effective September 23, 2013 the Company’s symbol for its common stock trading on the OTCQX trading platform will change to “IMNP”. The Company’s common stock had been required to trade under the symbol […]

Keep Reading

PRESS RELEASE September 4, 2013

Immune Pharmaceuticals Inc. Presenting At The 15th Annual Rodman & Renshaw Global Investment Conference In New York City September 8-10th, 2013

TARRYTOWN, N.Y., Sept. 4, 2013 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held September 8-10, 2013, at the Millennium […]

Keep Reading

PRESS RELEASE August 27, 2013

Immune Pharmaceuticals Restructures Secured Loan Following Completion of Merger

TARRYTOWN, N.Y., Aug. 27, 2013 /PRNewswire/ — Immune Pharmaceuticals Inc. (Nasdaq OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) (“Immune” or the “Company”) announced today that it has executed the Third Amendment and Consent to the Loan and Security Agreement between the Company  and MidCap Funding III, LLC (“MidCap”).  This amendment restructures the loan in connection with […]

Keep Reading

PRESS RELEASE August 26, 2013

Immune Pharmaceuticals Completes Merger with EpiCept Corporation

TARRYTOWN, N.Y., Aug. 26, 2013 /PRNewswire/ — Immune Pharmaceuticals Inc. (Nasdaq OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) (the “Company”) announced today the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation.  The merger combines Immune’s antibody therapeutic platform focused on the treatment of inflammatory diseases and cancer with EpiCept’s early stage cancer program […]

Keep Reading

PRESS RELEASE August 20, 2013

EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.

TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Aug. 20, 2013 /PRNewswire/ — EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) (the “Company”) and Immune Pharmaceuticals Ltd. announced today that, in accordance with EpiCept’s recent stockholder approval and in preparation for the closing of the merger between the two companies, the 1-for-40 reverse stock split of EpiCept’s […]

Keep Reading

PRESS RELEASE August 1, 2013

EpiCept Reports Second Quarter 2013 Operating and Financial Results

TARRYTOWN, N.Y., Aug. 1, 2013 /PRNewswire/ — EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today announced operating and financial results for the three and six months ended June 30, 2013, and provided an update on the Company’s upcoming merger with Immune Pharmaceuticals, Ltd. (Immune). Robert Cook, Interim President and CEO of EpiCept, commented, […]

Keep Reading

PRESS RELEASE June 20, 2013

EpiCept Issues Notice of Special Meeting of Stockholders on August 6 to Approve Important Aspects of the Proposed Merger with Immune Pharmaceuticals

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News : EpiCept Corporation (Nasdaq OMX Stockholm and OTCQX: EPCT) today issued notice that stockholders of EpiCept are invited to the Special Meeting of Stockholders (the “Special Meeting”) to be held on August 6, 2013 at 11:00 a.m. Eastern Daylight Time at the Company’s offices at 777 Old Saw Mill River […]

Keep Reading

PRESS RELEASE June 3, 2013

EpiCept Announces New Crolibulin Data Presented at ASCO 2013 Support Further Evaluation in Anaplastic Thyroid Cancer

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that new data supporting further evaluation of crolibulin were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO 2013), taking place May 31 to June 4, 2013 at the McCormick Place Convention Center in Chicago. Crolibulin […]

Keep Reading